{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:34:05Z","timestamp":1790872445334,"version":"4.1.0"},"reference-count":219,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005780","name":"Chitkara University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113508","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T06:05:15Z","timestamp":1731391515000},"page":"113508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P3","title":["From Manifestations to Innovations: A Deep Dive into Psoriasis, its Clinical Diversity, Conventional Treatments, and Emerging Therapeutic Paradigms"],"prefix":"10.1016","volume":"143","author":[{"given":"Sneha","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskan","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iresha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6061-3640","authenticated-orcid":false,"given":"Varinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113508_b0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/PTT.S328447","article-title":"Assessing and improving psychological well-being in psoriasis: considerations for the clinician","author":"Blackstone","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"key":"10.1016\/j.intimp.2024.113508_b0010","article-title":"Burden of psoriasis in young adults worldwide from the global burden of disease study 2019","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.04.139","article-title":"The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017","volume":"84","author":"Mehrmal","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0025","article-title":"Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends From 1990 to 2017","volume":"8","author":"Peng","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0030","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14656566.2023.2206014","article-title":"New synthetic pharmacotherapeutic approaches to the treatment of moderate-to-severe plaque psoriasis in adults","volume":"24","author":"Chandy","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: A systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14712598.2018.1479738","article-title":"Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future","volume":"18","author":"Raimondo","year":"2018","journal-title":"Expert opinion on biological therapy"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/jamadermatol.2023.6236","article-title":"Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis","volume":"160","author":"Egilman","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0050","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.jval.2024.03.578","article-title":"EE279 Cost-Effectiveness Analysis of Biosimilars and Novel Biologics for Patients With Moderate-to-Severe Psoriasis","volume":"27","author":"Leong","year":"2024","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0055","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/JLB.5MR0120-439R","article-title":"Keratinocyte: A trigger or an executor of psoriasis?","volume":"108","author":"Ni","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"17","key":"10.1016\/j.intimp.2024.113508_b0060","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.3390\/ijms22179294","article-title":"The role of epigenetic factors in psoriasis","volume":"22","author":"Dopytalska","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0070","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/15548627.2020.1725381","article-title":"Autophagy-based unconventional secretion of HMGB1 by keratinocytes plays a pivotal role in psoriatic skin inflammation","volume":"17","author":"Wang","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2024.113508_b0075","article-title":"An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis","volume":"638","author":"Hazari","year":"2023","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0080","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.3390\/ijms24054894","article-title":"Conundrum for Psoriasis and Thyroid Involvement","volume":"24","author":"Cira","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000527737","article-title":"New-Onset Guttate Psoriasis: A Long-Term Follow-Up Study","volume":"239","author":"Galili","year":"2023","journal-title":"Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0095","first-page":"953","article-title":"Inverse psoriasis: from diagnosis to current treatment options","author":"Micali","year":"2019","journal-title":"Clinical, cosmetic and investigational dermatology"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0100","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/exd.14770","article-title":"Pustular psoriasis in Malaysia: A review of the Malaysian Psoriasis Registry 2007\u20132018","volume":"32","author":"Teoh","year":"2023","journal-title":"Exp. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0105","first-page":"313","article-title":"A case of localized pustular psoriasis","volume":"19","author":"Choi","year":"2006","journal-title":"The Journal of Korean Medicine Ophthalmology and Otolaryngology and Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0110","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2147\/CCID.S407812","article-title":"Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?","author":"Megna","year":"2023","journal-title":"Clinical, cosmetic and investigational dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0115","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2147\/CCID.S417679","article-title":"Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments","author":"Battista","year":"2023","journal-title":"Clinical, Cosmetic and Investigational Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","article-title":"Palmoplantar psoriasis","volume":"35","author":"Engin","year":"2017","journal-title":"Clin. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4317\/jced.50905","article-title":"Journal section: Oral Medicine and Pathology Publication Types","volume":"4","author":"Darwazeh","year":"2012","journal-title":"J Clin Exp Dent"},{"issue":"8 Suppl ODAC Conf Pt 2","key":"10.1016\/j.intimp.2024.113508_b0130","first-page":"s101","article-title":"Scalp psoriasis","volume":"9","author":"Kircik","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/1756-185X.14474","article-title":"Current treatment strategies and recommendations in psoriatic arthritis","volume":"26","author":"Kao","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0140","first-page":"191","article-title":"Psoriasis complicated with severe mutilating psoriatic osteoarthropathy. Clinical case and review of the literature","volume":"91","author":"Iannello","year":"2000","journal-title":"Minerva medica"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0145","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-018-0354-9","article-title":"Clinical and Therapeutic Aspects of Linear Psoriasis: A Study of 30 Cases","volume":"19","author":"Say","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1525-1470.2002.00026.x","article-title":"Annular Pustular Psoriasis\u2014Most Common Form of Pustular Psoriasis in Children: Report of Three Cases and Review of the Literature","volume":"19","author":"Liao","year":"2002","journal-title":"Pediatr. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0155","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ccr3.2871","article-title":"Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports","volume":"8","author":"Al-Janabi","year":"2020","journal-title":"Clin Case Rep"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0160","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00296-024-05632-2","article-title":"Impact of comorbidities on patient-reported outcomes in psoriatic arthritis: a single centre cohort study","volume":"44","author":"Biedro\u0144","year":"2024","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2024.113508_b0165","first-page":"1","article-title":"Managing the Patient with Psoriasis and Metabolic Comorbidities","author":"Bellinato","year":"2024","journal-title":"American Journal of Clinical Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0170","doi-asserted-by":"crossref","unstructured":"Yu, Y., Liu, Y., Ni, Z., Ma, S. and Zhou, J., Bioinformatics analysis of the shared pathogenesis of psoriasis and Crohn's disease. 2023.","DOI":"10.21203\/rs.3.rs-3063476\/v1"},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0175","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.5455\/annalsmedres.2019.02.174","article-title":"Skin and Gut: Psoriasis and irritable bowel syndrome. Is there an association?","volume":"27","author":"Urun Unal","year":"2021","journal-title":"Annals of Medical Research"},{"key":"10.1016\/j.intimp.2024.113508_b0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/jdv.12165","article-title":"Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies","volume":"27","author":"Pouplard","year":"2013","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0185","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA dermatology"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0190","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1007\/s10620-024-08451-4","article-title":"The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn\u2019s Disease","volume":"69","author":"Janak","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","article-title":"Cancer risk in patients with psoriasis: should we be paying more attention?","volume":"16","author":"Loft","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b0200","first-page":"1","article-title":"Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities","author":"Potestio","year":"2024","journal-title":"Dermatology and Therapy"},{"key":"10.1016\/j.intimp.2024.113508_b0205","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241227037","article-title":"The association between psoriasis, psoriasis severity, and inflammatory bowel disease: a population-based analysis","volume":"17","author":"Shani","year":"2024","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0210","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/jdv.19567","article-title":"Implementing well-being in the management of psoriasis: An expert recommendation","volume":"38","author":"Sommer","year":"2023","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"key":"10.1016\/j.intimp.2024.113508_b0215","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.18332\/popmed\/165253","article-title":"The psoriasis comorbidome","volume":"5","author":"Miatton","year":"2023","journal-title":"Population Medicine"},{"key":"10.1016\/j.intimp.2024.113508_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1294056","article-title":"Psoriasis comorbidity management in the COVID era: a pressing challenge","volume":"14","author":"Song","year":"2023","journal-title":"Front. Microbiol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0225","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","article-title":"The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis","volume":"13","author":"Buja","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2024.113508_b0235","doi-asserted-by":"crossref","DOI":"10.1177\/26335565231212336","article-title":"Exploring comorbidity and pharmacological treatment patterns in psoriasis-a retrospective population-based cross-sectional study","volume":"13","author":"Hamg\u00e5rd","year":"2023","journal-title":"Journal of multimorbidity and comorbidity"},{"issue":"7","key":"10.1016\/j.intimp.2024.113508_b0240","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.drudis.2021.03.015","article-title":"Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases","volume":"26","author":"Ribeiro","year":"2021","journal-title":"Drug Discovery Today"},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0245","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1007\/s40520-022-02257-y","article-title":"SIRT1 activation and its circadian clock control: a promising approach against (frailty in) neurodegenerative disorders","volume":"34","author":"Ribeiro","year":"2022","journal-title":"Aging Clinical and Experimental Research"},{"key":"10.1016\/j.intimp.2024.113508_b0250","first-page":"71","article-title":"The Skin Microbiome and Its Role in Psoriasis: A Review","volume":"13","author":"Celoria","year":"2023","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0255","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09546634.2020.1729335","article-title":"Long-term topical management of psoriasis: the road ahead","volume":"33","author":"Segaert","year":"2022","journal-title":"J. Dermatol. Treat."},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0260","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15104","article-title":"Emerging paradigm shift toward proactive topical treatment of psoriasis: A narrative review","volume":"34","author":"Papp","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.intimp.2024.113508_b0265","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2147\/CCID.S254114","article-title":"Spotlight on topical long-term management of plaque psoriasis","volume":"13","author":"Carrascosa","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0270","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15685","article-title":"The role of lifestyle and nutrition in psoriasis: Current status of knowledge and interventions","volume":"35","author":"Musumeci","year":"2022","journal-title":"Dermatologic Therapy"},{"key":"10.1016\/j.intimp.2024.113508_b0275","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/PTT.S294189","article-title":"The effect of lifestyle changes on disease severity and quality of life in patients with plaque psoriasis: A narrative review","author":"van Acht","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"10","key":"10.1016\/j.intimp.2024.113508_b0280","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/1756-185X.14406","article-title":"Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates","volume":"25","author":"Alnaqbi","year":"2022","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.intimp.2024.113508_b0285","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/PTT.S328572","article-title":"Comorbidity in Adult Psoriasis: Considerations for the Clinician","volume":"12","author":"Daugaard","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0290","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/PTT.S293107","article-title":"Comorbid psoriasis and metabolic syndrome: clinical implications and optimal management","author":"De Brandt","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"key":"10.1016\/j.intimp.2024.113508_b0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: current progress","author":"Camela","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0305","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjd.20940","article-title":"Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis","volume":"186","author":"Luengas-Martinez","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0310","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/1744666X.2023.2141226","article-title":"Tailored biological treatment for patients with moderate-to-severe psoriasis","volume":"19","author":"Maurelli","year":"2023","journal-title":"Expert Review of Clinical Immunology"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0315","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/der2.87","article-title":"The future of personalized medicine in psoriasis","volume":"2","author":"Hong","year":"2021","journal-title":"Dermatological Reviews"},{"key":"10.1016\/j.intimp.2024.113508_b0320","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence?","volume":"182","author":"Korman","year":"2020","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0330","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"The Journal of dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102614","article-title":"Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities","volume":"118","author":"Srivastava","year":"2021","journal-title":"Journal of autoimmunity"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0340","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0345","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40257-020-00533-z","article-title":"Progress to Date in Advancing Stratified Medicine in Psoriasis","volume":"21","author":"Reid","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0350","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: current progress","author":"Camela","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0355","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/17425255.2016.1194394","article-title":"Pharmacogenetics and pharmacogenomics in psoriasis treatment: current challenges and future prospects","volume":"12","author":"Sutherland","year":"2016","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"13","key":"10.1016\/j.intimp.2024.113508_b0360","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2217\/pgs.13.163","article-title":"Pharmacogenetics of topical and systemic treatment of psoriasis","volume":"14","author":"Prieto-P\u00e9rez","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0365","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3390\/genes12091398","article-title":"Pharmacogenomics: an update on biologics and small-molecule drugs in the treatment of psoriasis","volume":"12","author":"Caputo","year":"2021","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.intimp.2024.113508_b0370","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1468-3083.2010.03932.x","article-title":"Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic","volume":"25","author":"Barker","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0375","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0380","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0385","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0390","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/ijd.16208","article-title":"Psoriasis caused by ocrelizumab in two persons with primary progressive multiple sclerosis","volume":"61","author":"Jakob Brecl","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.intimp.2024.113508_b0395","unstructured":"R. Yakubov et al., \u201cE M E R G I N G A U T H O R S I N D E R M ATO LO G Y for Psoriasis,\u201d vol. 14, no. 12, pp. 55\u201363, 2021."},{"key":"10.1016\/j.intimp.2024.113508_b0400","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/jvc2.178","article-title":"Ocrelizumab-induced psoriasiform dermatitis: Case reports and review of the literature","volume":"2","author":"Naranjo Guerrero","year":"2023","journal-title":"JEADV Clinical Practice"},{"key":"10.1016\/j.intimp.2024.113508_b0405","first-page":"1","article-title":"Anti-TNF Therapy","author":"Udalova","year":"2016","journal-title":"Microbiol Spectr."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0410","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/ced.14979","article-title":"Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice","volume":"47","author":"Ruggiero","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0415","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/FPC.0000000000000233","article-title":"HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients","volume":"26","author":"Caldarola","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0420","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ced.12323","article-title":"Genetic markers of treatment response to tumour necrosis factor-\u03b1 inhibitors in the treatment of psoriasis","volume":"39","author":"Ryan","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0425","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0430","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000136","article-title":"The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients","volume":"25","author":"Batalla","year":"2015","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.intimp.2024.113508_b0435","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-017-0274-z","article-title":"The Role of Pharmacogenetics in Chronic Plaque Psoriasis : Update of the Literature","author":"Talamonti","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.intimp.2024.113508_b0440","unstructured":"Janssen Biotech, \u201cSTELARA\u00ae (ustekinumab) injection prescribing information,\u201d 2016."},{"key":"10.1016\/j.intimp.2024.113508_b0445","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2147\/PTT.S367744","article-title":"Bimekizumab for the treatment of psoriasis: a review of the current knowledge","author":"Ruggiero","year":"2022","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0450","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/jdv.18913","article-title":"Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study \u2013 IL PSO (ITALIAN LANDSCAPE PSORIASIS)","volume":"37","author":"Gargiulo","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0455","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/jdv.15065","article-title":"Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey","volume":"32","author":"Armstrong","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2024.113508_b0460","doi-asserted-by":"crossref","first-page":"4861570","DOI":"10.1155\/2017\/4861570","article-title":"Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review","volume":"2017","author":"Janiczek","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0470","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjd.19380","article-title":"Role of regulatory T cells in psoriasis pathogenesis and treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0475","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis : A systematic review and meta-analysis of observational and clinical studies","author":"Alinaghi","year":"2018","journal-title":"Journal of American Dermatology"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0485","first-page":"367","article-title":"Understanding psoriasis: Role of miRNAs","volume":"9","author":"Timis","year":"2018","journal-title":"Biomedical reports"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0490","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.18632\/oncotarget.22260","article-title":"Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis","volume":"9","author":"Bai","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0495","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101108","article-title":"General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach","volume":"4","author":"Tha\u00e7i","year":"2020","journal-title":"BJGP open"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0500","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovascular research"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0510","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","article-title":"Psoriasis: a possible risk factor for development of coronary artery calcification","volume":"156","author":"Ludwig","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0515","first-page":"1","article-title":"Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","article-title":"Manifestations and Management of Difficult-to-Treat Psoriasis","volume":"10","author":"Aldredge","year":"2018","journal-title":"J Dermatol Nurses Assoc"},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0525","first-page":"28","article-title":"New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis","volume":"12","author":"Psomadakis","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0530","doi-asserted-by":"crossref","DOI":"10.1007\/s40261-024-01368-w","article-title":"Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","author":"de Moraes-Souza","year":"2024","journal-title":"Clin. Drug Invest."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0535","first-page":"827","article-title":"Comparative study of efficacy of topical anthralin (0.5%) and topical calcipotriol (0.005%) in management of chronic plaque psoriasis","volume":"33","author":"Naveed","year":"2023","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0540","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/ijd.16193","article-title":"Updated view of tars for psoriasis: what have we learned over the last decade?","volume":"62","author":"\u00c1valos-Viveros","year":"2023","journal-title":"Int. J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/2229-5178.209622","article-title":"Topical therapies in psoriasis","volume":"8","author":"Torsekar","year":"2017","journal-title":"Indian Dermatol. Online J."},{"issue":"15","key":"10.1016\/j.intimp.2024.113508_b0550","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/molecules27154964","article-title":"An overview of PDE4 inhibitors in clinical trials: 2010 to early 2022","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0555","doi-asserted-by":"crossref","first-page":"30","DOI":"10.25259\/IJDVL_15_2023","article-title":"Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease","volume":"90","author":"Huang","year":"2023","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0560","first-page":"21","article-title":"Challenges in psoriatic disease addressed by Fixed-Combination halobetasol propionate 0.01% and tazarotene 0.045% lotion","volume":"16","author":"Kircik","year":"2023","journal-title":"The Journal of Clinical and Aesthetic Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b0565","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/PTT.S393997","article-title":"Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream","author":"Spencer","year":"2023","journal-title":"Psoriasis: Targets and Therapy"},{"issue":"17","key":"10.1016\/j.intimp.2024.113508_b0570","doi-asserted-by":"crossref","first-page":"13313","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.intimp.2024.113508_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100123","article-title":"Promising prospects of lipid-based topical nanocarriers for the treatment of psoriasis","volume":"10","author":"Alam","year":"2023","journal-title":"OpenNano"},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0580","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/antibiotics12121698","article-title":"Innovative Approaches for Maintaining and Enhancing Skin Health and Managing Skin Diseases through Microbiome-Targeted Strategies","volume":"12","author":"Al-Smadi","year":"2023","journal-title":"Antibiotics"},{"issue":"10","key":"10.1016\/j.intimp.2024.113508_b0585","doi-asserted-by":"crossref","first-page":"462","DOI":"10.12968\/bjon.2023.32.10.462","article-title":"Psoriasis: Overview, treatments and implications for nursing care","volume":"32","author":"Hill","year":"2023","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.intimp.2024.113508_b0590","doi-asserted-by":"crossref","first-page":"122312","DOI":"10.1016\/j.biomaterials.2023.122312","article-title":"Delivery of biologics: Topical administration","author":"Kulchar","year":"2023","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0595","first-page":"1249","article-title":"Exploring novel therapeutics targets for psoriasis: Insights into pathogenesis and drug development","volume":"33","author":"Siddique","year":"2023","journal-title":"Journal of Pakistan Association of Dermatologists"},{"key":"10.1016\/j.intimp.2024.113508_b0600","unstructured":"\u201cStudy Details | A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04612699."},{"key":"10.1016\/j.intimp.2024.113508_b0605","unstructured":"\u201cStudy Details | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04999839."},{"key":"10.1016\/j.intimp.2024.113508_b0610","unstructured":"\u201cStudy Details | A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04855721."},{"key":"10.1016\/j.intimp.2024.113508_b0615","unstructured":"\u201cStudy Details | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05044234."},{"key":"10.1016\/j.intimp.2024.113508_b0620","unstructured":"\u201cStudy Details | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05352893#study-plan."},{"key":"10.1016\/j.intimp.2024.113508_b0625","unstructured":"\u201cStudy Details | EffisayilTM 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT03782792."},{"key":"10.1016\/j.intimp.2024.113508_b0630","unstructured":"\u201cStudy Details | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05172726."},{"key":"10.1016\/j.intimp.2024.113508_b0635","unstructured":"\u201cStudy Details | A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. | ClinicalTrials.gov.\u201d Accessed: Oct. 24, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05375955."},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0640","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0645","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0650","unstructured":"\u201cStudy Details | A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05194839."},{"issue":"10273","key":"10.1016\/j.intimp.2024.113508_b0655","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2024.113508_b0660","unstructured":"\u201cStudy Details | A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05003531."},{"key":"10.1016\/j.intimp.2024.113508_b0665","unstructured":"\u201cStudy Details | A Phase \u2162 Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT04839328."},{"key":"10.1016\/j.intimp.2024.113508_b0670","unstructured":"\u201cStudy Details | Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05268016."},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b0675","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1007\/s13555-022-00840-9","article-title":"A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians","volume":"12","author":"Drakos","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0680","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the treatment of psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J. Dermatol. Treat."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0685","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12026-022-09356-y","article-title":"Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data","volume":"71","author":"Ruggiero","year":"2023","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2024.113508_b0690","unstructured":"\u201cStudy Details | Study to Assess the Efficacy and Safety of Orismilast in Psoriasis | ClinicalTrials.gov.\u201d Accessed: Oct. 23, 2023. [Online]. https:\/\/clinicaltrials.gov\/study\/NCT05190419."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0695","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1021\/acs.molpharmaceut.2c00713","article-title":"Novel Synergistic Approach: Tazarotene-Calcipotriol-Loaded-PVA\/PVP-Nanofibers Incorporated in Hydrogel Film for Management and Treatment of Psoriasis","volume":"20","author":"Thakur","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.intimp.2024.113508_b0700","first-page":"1343","article-title":"Dendrimer entrapped microsponge gel of dithranol for effective topical treatment","volume":"5","author":"Kumar Tripathi","year":"2019","journal-title":"Heliyon"},{"key":"10.1016\/j.intimp.2024.113508_b0705","doi-asserted-by":"crossref","unstructured":"Z. Liu et al., \u201cUPLC-Q-TOF\/MS and Network Pharmacology-Based Study on the Mechanism of Qingre Lishi Decoction in Psoriasis Therapyuplc-Q-Tof\/Ms and Network Pharmacology-Based Study on the Mechanism of Qingre Lishi Decoction in Psoriasis Therapy\u201d, https:\/\/doi.org\/10.2139\/SSRN.4369310.","DOI":"10.2139\/ssrn.4369310"},{"key":"10.1016\/j.intimp.2024.113508_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114634","article-title":"Apremilast loaded lyotropic liquid crystalline nanoparticles embedded hydrogel for improved permeation and skin retention: An effective approach for psoriasis treatment","volume":"162","author":"Rapalli","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0715","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/jcs6080231","article-title":"Development and Characterization of Aloe vera Mucilaginous-Based Hydrogels for Psoriasis Treatment","volume":"6","author":"Jales","year":"2022","journal-title":"Journal of Composites Science"},{"key":"10.1016\/j.intimp.2024.113508_b0720","unstructured":"\u201c(1) (PDF) In-silico Approach for the Treatment of Psoriasis by Solanum xanthocarpum.\u201d Accessed: Oct. 19, 2023. [Online]. Available: https:\/\/www.researchgate.net\/publication\/374418956_In-silico_Approach_for_the_Treatment_of_Psoriasis_by_Solanum_xanthocarpum."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0725","doi-asserted-by":"crossref","first-page":"5","DOI":"10.53388\/LR20230005","article-title":"Molecular mechanism of Compound Qingdai Capsule in the treatment of psoriasis based on network pharmacology and molecular docking Corresponding to","volume":"6","author":"Li","year":"2023","journal-title":"Life Research"},{"key":"10.1016\/j.intimp.2024.113508_b0730","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2022.07.006","article-title":"Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis","volume":"349","author":"Mai","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2024.113508_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111605","article-title":"Topical delivery of clobetasol propionate loaded nanosponge hydrogel for effective treatment of psoriasis: Formulation, physicochemical characterization, antipsoriatic potential and biochemical estimation","volume":"119","author":"Kumar","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"issue":"30","key":"10.1016\/j.intimp.2024.113508_b0740","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb6049","article-title":"Treatment of psoriasis with NFKBIZ siRNA using topical ionic liquid formulations","volume":"6","author":"Mandal","year":"2020","journal-title":"Science advances"},{"issue":"6","key":"10.1016\/j.intimp.2024.113508_b0745","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/1744666X.2020.1776116","article-title":"Calcipotriol\/betamethasone dipropionate formulations for psoriasis: an overview of the options and efficacy data","volume":"16","author":"Megna","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0750","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1574884714666191017111218","article-title":"Formulation and Evaluation of Polyherbal Cream and Lotion for the Treatment of Psoriasis-Induced Secondary Infections","volume":"16","author":"Joshi","year":"2021","journal-title":"Curr. Rev. Clin. Exp. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113508_b0755","first-page":"1","article-title":"Formulation, development and evaluation of ibuprofen loaded nano-transferosomal gel for the treatment of psoriasis","volume":"31","author":"Abdallah","year":"2019","journal-title":"J. Pharm. Res"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0760","doi-asserted-by":"crossref","first-page":"188","DOI":"10.22270\/jddt.v10i5.4299","article-title":"Development and Characterization of Barbaloin Gel for the Safe and Effective Treatment of Psoriasis","volume":"10","author":"Singh","year":"2020","journal-title":"Journal of Drug Delivery and Therapeutics"},{"key":"10.1016\/j.intimp.2024.113508_b0765","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110352","article-title":"Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity","volume":"182","author":"Meng","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0770","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/pharmaceutics12040358","article-title":"Novel and modified neutrophil elastase inhibitor loaded in topical formulations for psoriasis management","volume":"12","author":"Nunes","year":"2020","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0775","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/08982104.2020.1748646","article-title":"Formulation and evaluation of a topical liposomal gel containing a combination of zedoary turmeric oil and tretinoin for psoriasis activity","volume":"31","author":"Chen","year":"2021","journal-title":"J. Liposome Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0780","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s13346-020-00852-y","article-title":"Novel nanoemulsion gel containing triple natural bio-actives combination of curcumin, thymoquinone, and resveratrol improves psoriasis therapy: in vitro and in vivo studies","volume":"11","author":"Khatoon","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.intimp.2024.113508_b0785","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.2147\/IJN.S247007","article-title":"Methotrexate-Loaded Nanostructured Lipid Carrier Gel Alleviates Imiquimod-Induced Psoriasis by Moderating Inflammation: Formulation, Optimization, Characterization, In-Vitro and In-Vivo Studies","volume":"15","author":"Agrawal","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.intimp.2024.113508_b0790","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2147\/CCID.S430621","article-title":"Rehmannioside A Inhibits TRAF6\/MAPK Pathway and Improves Psoriasis by Interfering with the Interaction of HaCaT Cells with IL-17A","volume":"16","author":"Yuan","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0795","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1038\/s41598-020-65689-4","article-title":"Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin","volume":"10","author":"\u017durauskas","year":"2020","journal-title":"Sci. Rep."},{"issue":"Supplement_6","key":"10.1016\/j.intimp.2024.113508_b0800","doi-asserted-by":"crossref","first-page":"vi38","DOI":"10.1093\/rheumatology\/keab504","article-title":"Integrating imaging and biomarker assessment to better define psoriatic arthritis and predict response to biologic therapy","volume":"60","author":"Elliott","year":"2021","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0805","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: classical and emerging comorbidities","volume":"90","author":"Oliveira","year":"2015","journal-title":"Anais brasileiros de dermatologia"},{"key":"10.1016\/j.intimp.2024.113508_b0810","article-title":"Inflammation biomarkers are associated with the incidence of cardiovascular disease: a meta-analysis","volume":"10","author":"Liu","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"11","key":"10.1016\/j.intimp.2024.113508_b0815","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3390\/jcm12113850","article-title":"Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review","volume":"12","author":"Kimak","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0820","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3390\/jcm12051801","article-title":"Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris","volume":"12","author":"Lee","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b0825","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5114\/reum.2022.120752","article-title":"The role of HLA-Cw6 in psoriasis and psoriatic arthritis","volume":"60","author":"Owczarek","year":"2022","journal-title":"Reumatologia\/rheumatology"},{"key":"10.1016\/j.intimp.2024.113508_b0830","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis","volume":"11","author":"Vecellio","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b0835","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1191645","article-title":"Pathogenic role of S100 proteins in psoriasis","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b0840","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.941071","article-title":"Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis","volume":"13","author":"Kamata","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b0845","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2017.11.002","article-title":"Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis","volume":"89","author":"Shi","year":"2018","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.intimp.2024.113508_b0850","article-title":"Cardiovascular Involvement in Psoriasis, Diagnosing Subclinical Atherosclerosis, Effects of Biological and Non-Biological Therapy: A Literature Review","volume":"12","author":"Valaiyaduppu Subas","year":"2020","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.intimp.2024.113508_b0855","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3390\/cells8080807","article-title":"Keratin 6, 16 and 17\u2014Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0860","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0865","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1752-1947-1-86","article-title":"Extensive psoriasis induced by pegylated interferon: A case report","volume":"1","author":"Citro","year":"2007","journal-title":"J Med Case Reports"},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0870","first-page":"394","article-title":"Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report","volume":"18","author":"Rathod","year":"2019","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.intimp.2024.113508_b0875","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/PTT.S417427","article-title":"Therapeutic Management of a Case of Severe Psoriasis Coexistent with Bullous Pemphigoid in the Elderly","author":"Di Lernia","year":"2023","journal-title":"Psoriasis: Targets and Therapy"},{"key":"10.1016\/j.intimp.2024.113508_b0880","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2147\/CCID.S417290","article-title":"Psoriasis on Lesions of Vitiligo: A Case Report","volume":"16","author":"Wang","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0885","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.sjbs.2014.09.004","article-title":"Treatment of psoriasis by using Hijamah: A case report","volume":"22","author":"Malik","year":"2015","journal-title":"Saudi J Biol Sci"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0890","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3892\/etm.2015.2631","article-title":"Efficacy of nutritional treatment in patients with psoriasis: A case report","volume":"10","author":"Wong","year":"2015","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.113508_b0895","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4103\/ijd.IJD_97_17","article-title":"Refractory psoriasis vulgaris with itching successfully treated with the anti-interleukin-17a antibody secukinumab: A case of secondary failure of other biologic agents","volume":"62","author":"Kurosaki","year":"2017","journal-title":"Indian J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0900","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000491572","article-title":"Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review","volume":"10","author":"De Bock","year":"2018","journal-title":"Case Rep. Dermatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0905","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaim.2020.11.009","article-title":"Potential implications of Ayurveda in Psoriasis: A clinical case study","volume":"12","author":"Nille","year":"2021","journal-title":"J Ayurveda Integr Med"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0910","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4103\/JISM.JISM_16_20","article-title":"Role of Nitya Virechana and Shaman Chikitsa in the management of Ekakushta with special respect to plaque psoriasis: A case study","volume":"8","author":"Bhende","year":"2020","journal-title":"Journal of Indian System of Medicine"},{"key":"10.1016\/j.intimp.2024.113508_b0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.amsu.2022.103961","article-title":"Two cases of Erythrodermic psoriasis treated with Golimumab","volume":"78","author":"Kudsi","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.intimp.2024.113508_b0920","article-title":"Case Report: Coexistence of bullous pemphigoid and psoriasis: Therapeutic challenge and IL17A-targeted parallel treatment strategy","volume":"10","author":"Drenovska","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"10.1016\/j.intimp.2024.113508_b0925","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.4568","article-title":"SARS-CoV-2 and guttate psoriasis: A case report and review of literature","volume":"9","author":"Ali","year":"2021","journal-title":"Clinical Case Reports"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0930","doi-asserted-by":"crossref","first-page":"169","DOI":"10.21760\/jaims.8.3.32","article-title":"Ayurveda is a single hope for Autoimmune disease Psoriasis: A Case Study","volume":"8","author":"Rahangdale","year":"2023","journal-title":"Journal of Ayurveda and Integrated Medical Sciences"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b0935","doi-asserted-by":"crossref","first-page":"81","DOI":"10.33545\/26164485.2023.v7.i2b.812","article-title":"Constitutional treatment of plaque psoriasis: A case report","volume":"7","author":"Sarkar","year":"2023","journal-title":"International Journal of Homoeopathic Sciences"},{"issue":"9","key":"10.1016\/j.intimp.2024.113508_b0940","doi-asserted-by":"crossref","first-page":"Sep","DOI":"10.1111\/dth.15684","article-title":"Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review","volume":"35","author":"Zhao","year":"2022","journal-title":"Dermatol. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0945","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15207","article-title":"Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature","volume":"35","author":"Burlando","year":"2022","journal-title":"Dermatologic Therapy"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13223-023-00811-5","article-title":"Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report","volume":"19","author":"Yang","year":"2023","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b0955","article-title":"Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2024.113508_b0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109945","article-title":"Preclinical study models of psoriasis: State-of-the-art techniques for testing pharmaceutical products in animal and nonanimal models","volume":"117","author":"Yadav","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b0965","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10753-023-01961-9","article-title":"Advance in Multi-omics Research Strategies on Cholesterol Metabolism in Psoriasis","volume":"47","author":"Guo","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2024.113508_b0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110242","article-title":"Single-cell technologies in psoriasis","volume":"264","author":"Cui","year":"2024","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b0975","first-page":"112","article-title":"Exploring Novel Therapies for Psoriasis Management: A Dermatological perspective","volume":"28","author":"Masa'deh","year":"2024","journal-title":"International Tinnitus Journal"},{"issue":"11","key":"10.1016\/j.intimp.2024.113508_b0980","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/rheumatology\/keaa283","article-title":"Using functional genomics to advance the understanding of psoriatic arthritis","volume":"59","author":"Shi","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2024.113508_b0985","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.815121","article-title":"Genome-wide association study of ustekinumab response in psoriasis","volume":"12","author":"Connell","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.intimp.2024.113508_b0990","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.815121","article-title":"Genome-Wide Association Study of Ustekinumab Response in Psoriasis","volume":"12","author":"Connell","year":"2022","journal-title":"Front. Immunol."},{"issue":"29","key":"10.1016\/j.intimp.2024.113508_b1000","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.2174\/0929867330666230503143824","article-title":"The Epigenetic Contribution to the Pathogenesis of Psoriasis: Recent Advances","volume":"31","author":"Aslani","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"13","key":"10.1016\/j.intimp.2024.113508_b1005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137349","article-title":"Functional Genomics in Psoriasis","volume":"25","author":"Rossi","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.intimp.2024.113508_b1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2024.08.006","article-title":"Resolving 3-Dimensional Genomic Landscape of CD4+ T Cells in the Peripheral Blood of Patients with Psoriasis","author":"Qiu","year":"2024","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b1015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jid.2023.06.194","article-title":"Genomic profiling of the overlap phenotype between psoriasis and atopic dermatitis","volume":"144","author":"Kim","year":"2024","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b1020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"Journal of dermatological science"},{"issue":"12","key":"10.1016\/j.intimp.2024.113508_b1025","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs","volume":"29","author":"Ovejero-Benito","year":"2020","journal-title":"Experimental Dermatology"},{"issue":"5","key":"10.1016\/j.intimp.2024.113508_b1030","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jaci.2021.04.021","article-title":"Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets","volume":"148","author":"Kim","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b1035","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","article-title":"Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis","volume":"152","author":"Kim","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1016\/j.intimp.2024.113508_b1040","article-title":"Defining Patient-Level Molecular Heterogeneity in Psoriasis Vulgaris Based on Single-Cell Transcriptomics","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_b1045","article-title":"Defining patient-level molecular heterogeneity in psoriasis vulgaris based on single-cell transcriptomics","volume":"13","author":"Liu","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.intimp.2024.113508_b1050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109771","article-title":"Architecture of skin inflammation in psoriasis revealed by spatial transcriptomics","volume":"256","author":"Gniadecki","year":"2023","journal-title":"Clinical Immunology"},{"issue":"11","key":"10.1016\/j.intimp.2024.113508_b1055","doi-asserted-by":"crossref","first-page":"2250354","DOI":"10.1002\/eji.202250354","article-title":"Single-cell transcriptomics reveals prominent expression of IL-14, IL-18, and IL-32 in psoriasis","volume":"53","author":"Frost","year":"2023","journal-title":"European Journal of Immunology"},{"issue":"10","key":"10.1016\/j.intimp.2024.113508_b1060","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.3390\/genes11101155","article-title":"Transcriptome profiling analyses in psoriasis: a dynamic contribution of keratinocytes to the pathogenesis","volume":"11","author":"Rioux","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.intimp.2024.113508_b1070","article-title":"Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Proliferation and Inflammatory Response of Keratinocytes in Psoriasis","author":"Zheng","year":"2024","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.intimp.2024.113508_b1075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000533981","article-title":"Proteins in the skin and blood in patients with psoriasis: a systematic review of proteomic studies","volume":"240","author":"Kromann","year":"2024","journal-title":"Dermatology"},{"key":"10.1016\/j.intimp.2024.113508_b1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114359","article-title":"Analytical approaches to assess metabolic changes in psoriasis","volume":"205","author":"\u0141uczaj","year":"2021","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b1085","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/biomedicines10030619","article-title":"Proteomic studies of psoriasis","volume":"10","author":"Sobolev","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.intimp.2024.113508_b1090","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/jdv.18292","article-title":"iTRAQ-based quantitative proteomics reveals biomarkers\/pathways in psoriasis that can predict the efficacy of methotrexate","volume":"36","author":"Yan","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113508_b1095","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.21873\/invivo.13533","article-title":"Proteomics in Psoriasis: Recent Advances","volume":"38","author":"Leotsakos","year":"2024","journal-title":"in vivo"},{"issue":"1","key":"10.1016\/j.intimp.2024.113508_b1100","doi-asserted-by":"crossref","first-page":"2248318","DOI":"10.1080\/09546634.2023.2248318","article-title":"Potential biomarkers for psoriasis topical treatment by in-depth serum proteomics","volume":"34","author":"Cui","year":"2023","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1016\/j.intimp.2024.113508_b1105","article-title":"Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies","volume":"8","author":"Qi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.intimp.2024.113508_b1110","first-page":"1","article-title":"Mass Spectrometry-Based Proteomics Analysis Unveils PTPRS Inhibits Proliferation and Inflammatory Response of Keratinocytes in Psoriasis","author":"Zheng","year":"2024","journal-title":"Inflammation"},{"key":"10.1016\/j.intimp.2024.113508_b1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110305","article-title":"Metabolomic and lipidomic fingerprints in inflammatory skin diseases \u2013 Systemic illumination of atopic dermatitis, hidradenitis suppurativa and plaque psoriasis","volume":"265","author":"Rischke","year":"2024","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.intimp.2024.113508_bib1116","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10103-017-2360-1","article-title":"A clinical review of phototherapy for psoriasis","volume":"33","author":"Zhang","year":"2018","journal-title":"Lasers in medical science"},{"key":"10.1016\/j.intimp.2024.113508_bib1117","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.ijbiomac.2018.07.021","article-title":"Protein biomarker for psoriasis: A systematic review on their role in the pathomechanism, diagnosis, potential targets and treatment of psoriasis","volume":"118","author":"Yadav","year":"2018","journal-title":"International journal of biological macromolecules"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924020307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T04:21:41Z","timestamp":1733977301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924020307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":219,"alternative-id":["S1567576924020307"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113508","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From Manifestations to Innovations: A Deep Dive into Psoriasis, its Clinical Diversity, Conventional Treatments, and Emerging Therapeutic Paradigms","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113508"}}